Interventional Glaucoma

MIGS drainage device offers hope for challenging cases.

Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

Measurements from multiple studies show benefits of rho-kinase inhibition.

Increased access is key to preventing disease progression in patients.

Minimally invasive glaucoma surgery (MIGS) is appealing to glaucoma patients and surgeons; however, it should not be adopted without further high-quality research and careful reporting. Selection of the appropriate treatment for individual patients must be evidence based.

Implandata received FDA Breakthrough Device Designation for its Eyemate-SC in April and now has CE Mark approval in the European Union.

Visible-light optical coherence tomography proves valuable in studies.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

Physicians are left to determine which treatments can offer patients best outcomes.

Retrospective review highlights the sustained efficacy of combination procedure.

Two randomised controlled trials, EMGT and UKGTS, have examined the factors affecting the risk of glaucoma progression. Global target IOPs are not the best option for all patients.

Option could prove to enhance safety for both patients and staff.

According to preliminary results, intranasally delivered ST266 is a safe treatment option.

Use of such procedures increased markedly in analysis of IRIS Registry Data.

Careful study of ocular anatomy can help surgeons avoid problems related to glaucoma procedures and achieve better results for patients.

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, offers an update on optimization and surgical modifications of newer glaucoma surgeries in preop and postop settings.

Virtual reality, home visual field testing offer new options for physicians.

Research teams in various countries are pioneering different methods of data processing and deep-learning AI to create new models of care.

Investigators determine that patient rates of adherence with gonioscopy are low.

Ophthalmologists and industry KOLs share what lingers on their minds at the end of the day.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Ophthalmologist details his preferred technique to avoid complications during procedure.

Short learning curve, significant clinical advantages make this a comfortable addition.